The Liver Meeting 2019-Cirrhotic Cardiomyopathy

Video Transcription

Video Summary

Dr. Menhao Itzi, an assistant professor at Vanderbilt University, discussed cirrhotic cardiomyopathy in a presentation. Cirrhotic cardiomyopathy is defined as cardiac muscle dysfunction in patients with cirrhosis without a known cardiac disease. The pathophysiology involves myocardial fibrosis, myocardial hypertrophy, and subendocardial edema. Dr. Itzi highlighted studies showing the development of myocardial fibrosis in cirrhotic patients, potentially due to hepatic and myocardial inflammation and oxidative stress. He also discussed how the new criteria for diagnosing cirrhotic cardiomyopathy include assessing ejection fraction and diastolic dysfunction. The impact of strain imaging, ejection fraction cutoffs, and diastolic dysfunction on patient outcomes post liver transplant were also addressed. Dr. Itzi stressed the importance of monitoring cardiac function post-transplant and considering interventions such as ACE inhibitors or ARBs if necessary. The session concluded with a panel discussion on various aspects of cirrhotic cardiomyopathy, including diagnostic challenges and nutritional interventions for patients with cirrhosis.

Asset Caption

Presenter: Manhal Izzy

Keywords

cirrhotic cardiomyopathy

Dr. Menhao Itzi

Vanderbilt University

cardiac muscle dysfunction

myocardial fibrosis

ejection fraction

diastolic dysfunction